About QurAlis
QurAlis is a company based in Cambridge (United States) founded in 2016 by Clifford J Woolf and Kasper Roet.. QurAlis has raised $155.45 million across 7 funding rounds from investors including Amgen, EQT and HHS. The company has 38 employees as of December 31, 2022. QurAlis offers products and services including FlexASO® Platform and QRL-101. QurAlis operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 38 as on 31 Dec, 2022
- Founders Clifford J Woolf, Kasper Roet
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Quralis Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$155.45 M (USD)
in 7 rounds
-
Latest Funding Round
$19.95 M (USD), Series B
Aug 21, 2025
-
Investors
Amgen
& 18 more
-
Employee Count
38
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of QurAlis
QurAlis offers a comprehensive portfolio of products and services, including FlexASO® Platform and QRL-101. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Proprietary platform for anti-sense oligonucleotide therapies
Therapy targeting Kv7 for ALS treatment
Unlock access to complete
Unlock access to complete
Funding Insights of QurAlis
QurAlis has successfully raised a total of $155.45M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $19.95 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series B — $20.0M
-
First Round
First Round
(05 Apr 2018)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2025 | Amount | Series B - QurAlis | Valuation |
investors |
|
| Mar, 2023 | Amount | Series B - QurAlis | Valuation | EQT , Sanofi Ventures | |
| Sep, 2022 | Amount | Grant - QurAlis | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in QurAlis
QurAlis has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, EQT and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
EQT is recognized as a global investment organization focused on value creation.
|
Founded Year | Domain | Location | |
|
Private equity investments in life sciences businesses are managed.
|
Founded Year | Domain | Location | |
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by QurAlis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - QurAlis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Quralis Comparisons
Competitors of QurAlis
QurAlis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Quralis
Frequently Asked Questions about QurAlis
When was QurAlis founded?
QurAlis was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is QurAlis located?
QurAlis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of QurAlis?
Kasper Roet is the current CEO of QurAlis. They have also founded this company.
Is QurAlis a funded company?
QurAlis is a funded company, having raised a total of $155.45M across 7 funding rounds to date. The company's 1st funding round was a Grant of $300K, raised on Apr 05, 2018.
How many employees does QurAlis have?
As of Dec 31, 2022, the latest employee count at QurAlis is 38.
What does QurAlis do?
QurAlis is engaged in discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), which is a common form of motor neuron disease. The company has developed Optopatch technology which helps in stimulating the neurons and notes their electrical behavior. Their proprietary method clears toxic proteins and transcranial magnetic stimulation helps in diagnosing ALS by identifying biomarkers such as protein in the blood. In addition, other therapeutic targets like nerve threshold tracking, proteins in the cerebral spinal fluid helps to predict ALS. The company has a preclinical-stage program for ALS drugs targeting the Kv7.27.3 channel CSF cartridge device to remove DPR proteins.
Who are the top competitors of QurAlis?
QurAlis's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does QurAlis offer?
QurAlis offers FlexASO® Platform and QRL-101.
Who are QurAlis's investors?
QurAlis has 19 investors. Key investors include Amgen, EQT, HHS, Life Sciences Partners, and Viva BioInnovator.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.